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Platelets mediate hemostasis and are crucial for 
appropriate inflammatory and immune responses 
(Semple and Freedman, 2010). Platelets express 
several TLRs (Cognasse et al., 2005) including 
TLR9, which binds unmethylated bacterial and 
viral DNA (Iwasaki and Medzhitov, 2004). The 
discovery of immunostimulatory properties of 
specialized bacterial and mammalian DNA mo-
tifs that bind TLR9 (Hemmi et al., 2000) and 
regulate protective immune defense mechanisms 
has provided new options for prophylaxis and/or 
therapy for infectious, allergic, and malignant dis-
eases (Krieg et al., 1995). Short single-stranded 
DNA molecules (oligonucleotides) were devel-
oped as potential drug candidates. To prevent 
these oligonucleotides from being rapidly de-
graded by cellular and/or plasma nucleases, phos-
phorothioate (PS) modification was used whereby 
nonbridging oxygen molecules are replaced with 
sulfur (Lennox and Behlke, 2011). We investi-
gated the consequences of exposure of platelets 
to TLR9 agonists and other therapeutic oligo-
nucleotides and discovered an unexpected, PS 
modification–dependent activation of platelets 
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Nucleotide-based drug candidates such as antisense oligonucleotides, aptamers, immuno-
receptor-activating nucleotides, or (anti)microRNAs hold great therapeutic promise for many 
human diseases. Phosphorothioate (PS) backbone modification of nucleotide-based drugs is 
common practice to protect these promising drug candidates from rapid degradation by 
plasma and intracellular nucleases. Effects of the changes in physicochemical properties 
associated with PS modification on platelets have not been elucidated so far. Here we report 
the unexpected binding of PS-modified oligonucleotides to platelets eliciting strong platelet 
activation, signaling, reactive oxygen species generation, adhesion, spreading, aggregation, 
and thrombus formation in vitro and in vivo. Mechanistically, the platelet-specific receptor 
glycoprotein VI (GPVI) mediates these platelet-activating effects. Notably, platelets from 
GPVI function–deficient patients do not exhibit binding of PS-modified oligonucleotides, and 
platelet activation is fully abolished. Our data demonstrate a novel, unexpected, PS backbone–
dependent, platelet-activating effect of nucleotide-based drug candidates mediated by GPVI. 
This unforeseen effect should be considered in the ongoing development programs for the 
broad range of upcoming and promising DNA/RNA therapeutics.
© 2015 Flierl et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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Fig. 1 b), and platelet aggregation (Fig. 1 c). In contrast, 
ODN2395 binding to leukocytes was low, with only CD14+ 
cells demonstrating weak binding, which did not result in 
monocyte activation as assessed in flow cytometry using the 
single-chain antibody MAN-1, which binds selectively 
to the active conformation of integrin Mac-1 (not depicted; 
Eisenhardt et al., 2007). Unexpectedly, platelet activation was 
sequence (not depicted)- and TLR9-independent (Fig. 1, d and e) 
but required PS backbone modifications of oligonucleotides. 
mediated by the platelet-specific collagen receptor glycopro-
tein VI (GPVI), a signaling/adhesion receptor with important 
roles in platelet function.
RESULTS AND DISCUSSION
PS backbone modification induces platelet activation
Incubation of the PS oligodeoxynucleotides (ODNs [ODN2395]) 
with human platelets demonstrated concentration-dependent 
binding (Fig. 1 a), platelet activation (P-selectin up-regulation; 
Figure 1. ODN2395 binding to platelets and induction of platelet activation, aggregation, and adhesion. (a) ODN2395 was incubated with 
platelets and binding was assessed (***, P < 0.001 vs. background [BG], 10 µM non–PS-modified ODN2395 [“ODN2395 nonmod”], and 50 nM ODN2395; 
n = 6). (b) CD62P surface expression after ODN2395 incubation of human washed platelets compared with unstimulated control samples and ODN2395 
nonmod (*, P < 0.05 vs. unstimulated/1–10 µM ODN2395 nonmod/50 nM ODN2395; ***, P < 0.001 vs. unstimulated/1–10 µM ODN2395 nonmod/50 nM 
ODN2395; n = 5). (c) Platelet aggregation after 5 µM ODN2395 stimulation of PRP; final aggregation compared with 5 µM ADP/1 µg/ml collagen stimu-
lation; representative aggregation curves (n = 6). (d) Murine GPIIb/IIIa activation after incubation with ODN2395 (1 µM/5 µM; *, P < 0.05/***, P < 0.001 
vs. unstimulated WT/TRL9/; n = 4–5) detected on platelets from WT or mice deficient in TLR9 (TRL9/) using a single chain antibody (scFvSCE5), which 
binds to activated murine GPIIb/IIIa. (e) Binding of 1 or 5 µM ODN2395 to platelets from WT and TRL9/ mice (1 µM/5 µM; ***, P < 0.001 vs. BG WT/
TRL9/; n = 4–5). (f) Coincubation of 1-µm streptavidin beads alone (I) or beads coated with ODN2395 (II) or ODN2395 nonmod (III) with human 
washed platelets assessed for binding and activation of platelets by ODN2395-coated beads; representative dot blots and histograms of four indepen-
dently performed experiments are shown. (g) Whole blood incubation with ODN2395 on PMA formation (*, P < 0.05; **, P < 0.01; ***, P < 0.001 vs. un-
stimulated; n = 10). (h) DIC microscopy of washed human platelets adhering to 30 µg/ml fibrinogen–coated glass slides at the indicated time points; 
ODN2395 vs. nonmodified ODN2395 (labeled as ODN nonmod); shown is one representative experiment (n = 3). Bar, 2 µm. (i) Intraplatelet ROS produc-
tion after treatment with 10 µg/ml CRP-XL (positive control), 5 µM ODN2395, or 5 µM ODN nonmod (*, P < 0.05 vs. unstim./ODN nonmod; **, P < 0.01 
vs. ODN; n = 3). Data are presented as means ± SEM.
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ITAMs. FcRIIa is not present on mouse platelets (McKenzie 
et al., 1999). ODN2395-mediated platelet activation was sig-
nificantly attenuated by platelet pretreatment with Src kinase 
inhibitor PP2 or Syk inhibitor BAY 61-3606 at concentra-
tions previously shown to specifically block Src and Syk ac-
tivity in platelets (Fig. 2 d; Hu et al., 2011). Moreover, rapid 
tyrosine phosphorylation of the GPVI-associated FcR chain 
and several other intracellular proteins occurs upon GPVI 
cross-linking by collagen (Gibbins et al., 1996). Lysates of 
ODN2395-treated platelets exhibited significant phosphory-
lation of Syk and Src kinases, resembling the extent of phos-
phorylation observed in lysates treated with cross-linked 
collagen-related peptide (CRP [CRP-XL]), a GPVI-specific 
agonist (Fig. 2 e). ODN2395-dependent phosphorylation of 
Syk and Src was further confirmed by immunoprecipitation 
of phosphorylated tyrosine proteins and specific Western 
blots for these kinases (not depicted). Protein phosphoryla-
tion events induced by ODN2395 were delayed (5 min) 
compared with CRP-XL–induced tyrosine phosphorylation, 
consistent with the observed delayed response in ODN2395-
induced platelet aggregation (Fig. 1 c), as GPVI clustering 
and oligomerization is essential to elicit a full GPVI signaling 
response and platelet activation. This delayed response is 
likely to reflect the ability of ODN2395 to affect receptor 
clustering, an outcome which will be influenced by the affinity/
avidity and kinetics of PS ODN binding to GPVI, the extent 
of PS ODN oligomerization, and donor-variable GPVI 
surface density.
Collectively, the platelet counter-receptor for PS ODNs 
was likely to be an ITAM signaling receptor, most probably 
GPVI. This hypothesis was substantiated by the binding of 
a dimeric GPVI-Fc construct incorporating amino acids 
1–236 of human GPVI to immobilized ODN2395 (Fig. 2 f; 
Grüner et al., 2005). Pull-down experiments using GPVI-Fc 
and beads coated with PS-modified or nonmodified ODN2395 
confirmed GPVI as a specific binding partner for PS ODNs 
(Fig. 2 g).
GPVI is a receptor for PS-modified ODNs
To further define the role of GPVI as a receptor that mediates 
ODN2395 activity, we used the unique opportunity to obtain 
blood from patients with GPVI deficiency. Blood of two pa-
tients without medication, with mild bleeding symptoms, 
normal platelet counts, and normal response to adenosine di-
phosphate (ADP) and ristocetin but not collagen or CRP-XL 
in platelet aggregometry, was investigated (not depicted). Flow 
cytometry revealed normal platelet surface levels of GPIb 
and integrin IIb, but only 10% of levels of GPVI measured 
in a healthy donor analyzed on the same day (not depicted). 
Patient platelet lysates contained normal amounts of ITAM-
containing CLEC-2 as detected by Western blot (not depicted). 
Platelet-rich plasma (PRP) from GPVI-deficient patients did 
not support ODN2395/platelet binding or activation even at 
oligonucleotide concentrations up to 10 µM (Fig. 2 h), strongly 
suggesting that GPVI is a platelet receptor for ODN2395. Con-
sistent with this are our findings that pretreatment of healthy 
Oligonucleotides with a native phosphodiester backbone 
(ODN2395 nonmodified [nonmod]) did not bind (Fig. 1 a) 
or activate (Fig. 1 b) platelets. Platelets bound to ODN2395 
immobilized on beads demonstrated significantly increased 
binding of the platelet activation–specific mAb PAC-1 (GPIIb/
IIIa activation; Fig. 1 f). Elevated levels of platelet-monocyte 
aggregates (PMAs), reflecting clinically relevant platelet acti-
vation (Tapp et al., 2012), were significantly increased in 
whole blood when mixed with ODN2395 (Fig. 1 g) but not 
ODN2395 nonmod (not depicted). Treatment of human plate-
lets with ODN2395 also resulted in more rapid adhesion and 
spreading on fibrinogen (Fig. 1 h) and production of reactive 
oxygen species (ROS), mirroring the effects typically seen for 
GPVI ligands (Fig. 1 i; Arthur et al., 2012).
PS substitution can alter RNA/DNA conformation, pro-
tein binding properties, and physicochemical properties (Krieg 
et al., 2003). Substitution of a nonbridging oxygen atom with 
a sulfur atom in the phosphodiester backbone introduces chi-
rality around the phosphorus atom, and the number of diaste-
reomers produced by this chirality is 2n, where n is the number 
of PS links introduced (Eckstein, 2000). With 22 PS modi-
fications, ODN2395 potentially contains 222 (or 4,194,304) dia-
stereomers. The sulfur atom has a larger van der Waal’s radius 
(1.8 compared with 1.4 Å) and sulfur-phosphorus bond 
length (1.9 compared with 1.5 Å) than oxygen (Eckstein, 2000). 
The sulfur atom is less electronegative than oxygen (respec-
tively, 2.5 and 3.5 on the Pauling scale), but the negative 
charge is more confined to the sulfur atom, making the PS 
ODN backbone more “polyanionic” than the native phos-
phodiester. The PS ODN sulfur can participate in strong 
hydrogen bonding with a longer bond length than the equiv-
alent phosphodiester ODN. Together these physicochemi-
cal differences may permit specific binding of PS ODNs to 
cellular proteins.
PS modification causes receptor-mediated  
signaling in platelets
To assess the effects of ODN2395 on in vitro thrombus 
formation, anticoagulated whole blood was passed across col-
lagen- or fibrinogen-coated microchannels. ODN2395, but 
not nonmod ODN2395, caused rapid and extensive throm-
bus formation (Fig. 2 a). As platelet-specific GPIb of the 
GPIb-IX-V complex activates platelets when engaged by von 
Willebrand factor (VWF) under flow, we assessed a role for 
GPIb in mediating ODN2395 effects. Washed platelets were 
treated with Naja kaouthia metalloprotease Nk, which specif-
ically removes the N-terminal VWF-binding region of GPIb. 
Untreated and Nk-treated platelets bound ODN2395 effec-
tively and were activated to the same extent (Fig. 2, b and c), 
indicating that GPIb is not involved in mediating ODN2395-
induced activation.
Investigating the kinases Syk and Src allows us to draw 
conclusions about their upstream receptors, the so-called 
immunoreceptor tyrosine-based activation motif (ITAM) 
receptors. Human platelets express GPVI, C-type lectin-
like receptor 2 (CLEC-2), and FcRIIa, which signal through 
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A site-directed mutagenesis study has identified residues in 
the GPVI collagen-binding domain (CBD) that are involved 
with collagen or CRP binding (Horii et al., 2006). These resi-
dues are located in a groove on domain D1 of each monomer 
in the CBD; this groove is lined by basic residues, is electro-
positive, and would be an ideal site for the anionic (negatively 
donor platelets with function-blocking antibodies against 
human CLEC-2 or CD36 did not ablate ODN2395 binding 
or activation of platelets; however, pretreatment with the 
function-blocking anti-GPVI antibody (9012.2; Mangin et al., 
2012) prevented ODN2395-induced platelet aggregation 
(not depicted).
Figure 2. ODN2395-induced signaling 
and GPVI as target receptor of PS oligo-
nucleotides. (a) Platelet adhesion and throm-
bus formation under flow conditions after 
ODN2395 preincubation: collagen coating 
(100 µg/ml; left), fibrinogen coating (100 µg/ml; 
right), untreated control (top), 5 µM ODN2395 
(middle), and 5 µM ODN2395 nonmod (bot-
tom; n = 3). Bar, 50 µm. (b and c) Platelet 
activation/binding of ODN2395 after preincu-
bation with Nk protease (n = 4). (d) Impact of 
Syk kinase inhibitor Bay 61-3606 (5 µM) and 
the Src kinase inhibitor PP2 (5 µM) on further 
downstream signaling (***, P < 0.001 vs. pre-
incubated sample with Syk/Src kinase inhibi-
tors; n = 4–5). (e) Phosphorylation of Syk/Src 
after PS ODN incubation (5 µM) of platelets 
compared with control and ODN nonmod–
incubated samples; 5 µg/ml CRP-XL served as 
positive control (shown is one representative 
experiment; n = 4). (f) Binding of GPVI fusion 
construct (GPVI-Fc) to ODN2395-coated 
beads compared with uncoated/ODN non-
mod–coated beads; a recombinant human 
ICAM-1 Fc chimera, which shares ectodomain 
conformational similarities with GPVI, served 
as a control (shown is one representative 
histogram; n = 3). (g) Pull-down assays iden-
tified GPVI as a binding partner for ODN2395; 
representative Western blot detecting GPVI 
(n = 2). (h) Extent of platelet activation (histo-
gram) and ODN2395 binding (dot blots) to 
human GPVI-deficient platelets (shown are 
representative histograms/dot blots obtained 
from two GPVI-deficient patients). (i) Crystal 
structure of the GPVI CBD dimer and putative 
interactions with ODN2395 (orange)/CRP 
(red). (j) 5 µM ODN2395–induced GPVI dimer 
formation detected by binding of an anti-
GPVI dimer-specific Fab (204-FAB; shown is 
one representative experiment; n = 3). Data 
are presented as means ± SEM.
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Relevance for PS-modified, nucleotide-based therapeutics
Prompted by the observation that the PS backbone modifica-
tion of TLR9 agonistic ODNs has a major impact on platelet 
activation, we investigated a range of nucleotide-based thera-
peutics including oligonucleotides, aptamers, and miRNA 
mimetics/antagonists. The therapeutic potential of miRNA 
for multiple diseases has attracted major interest (van Rooij 
and Olson, 2012). Their inhibition can be achieved by de-
signing antisense oligonucleotides, which directly bind to and 
inactivate targeted miRNAs (van Rooij and Olson, 2012). 
PS modifications are used in miRNA therapeutics to achieve 
protection and stability against proteases and nucleases (Lennox 
and Behlke, 2011; van Rooij and Olson, 2012). To assess 
whether miRNA therapeutics can cause platelet activation, 
platelets were incubated with PS-modified miR-322 and 
demonstrated significant concentration-dependent binding 
of PAC-1 (Fig. 3 e), in agreement with a PS backbone but 
not a specific nucleotide sequence or TLR9 binding causing 
platelet activation.
Most of the antisense oligonucleotides used in clinical tri-
als carry a PS-modified backbone and reach plasma concen-
trations approaching 5 µM after i.v. infusion (Chi et al., 2005; 
Marcucci et al., 2005). The BCL-2–targeting PS-modified 
oblimersen (G3139) is one of the most widely studied anti-
sense oligonucleotides, which is administered i.v. for the 
treatment of chronic lymphocytic leukemia (Advani et al., 
2011) and melanoma (Ott et al., 2013). We observed signifi-
cant binding and activation of washed platelets by final con-
centrations of 50–100 nM G3139 (not depicted), and although 
G3139 is described to be highly protein-bound (Advani et al., 
2011), significant effects on platelets in whole blood assays at 
input concentrations of 1 µM were observed (Fig. 3, f and g). 
Although no severe thromboembolic complications have 
been reported so far with oblimersen, side effects include 
pyrexia, hypotension, and thrombocytopenia. The reported 
thrombotic events were classified as catheter-related compli-
cations (Advani et al., 2011), possibly related to drug dosing. 
The maximal plasma concentration of oblimersen, measured 
after 7 mg/kg continuous i.v. infusion, was 0.84 ± 0.6 µM 
(Marcucci et al., 2005). Our data show significant effects of 
ODN2395 in vitro in whole blood assays (Fig. 1 g), as well as 
assays in vivo in mice treated to attain an ODN2395 plasma 
concentration of 1 µM (Fig. 3 a). Antisense oligonucleotide 
plasma concentrations vary considerably between patients 
(Marcucci et al., 2005), implying that plasma concentrations 
sufficient to cause platelet activation are attainable.
In conclusion, we report a previously unrecognized mech-
anism of platelet activation mediated through PS backbone 
modifications of DNA and RNA oligonucleotides. GPVI 
binds modified oligonucleotides and mediates platelet effects. 
Sulfur replacements of the nonbinding oxygen have also been 
identified in some pathogenic bacteria as a postreplicative 
change (Wang et al., 2007). Thus, our findings may also rep-
resent a potential mechanism for platelet activation in bacte-
remia. As PS modification is a common step in many drug 
development programs, the described platelet-activating effects 
charged) ODN2395 to bind. We used the crystal structure 
(Horii et al., 2006) of the GPVI CBD dimer to model 
ODN2395 interactions (Fig. 2 i). A three-dimensional model of 
ODN2395 was constructed in a random, linear-like conforma-
tion and manually docked into the collagen-binding groove 
on D1 of a GPVI monomer (Fig. 2 i). A CRP molecule was 
similarly docked into the groove on D1 (Fig. 2 i), resulting in 
a CRP-GPVI model consistent with that previously reported 
(Horii et al., 2006). The linear-like conformation of ODN2395 
and CRP have similar diameters (10–12 Å), and the nega-
tively charged PS backbone of ODN2395 was able to interact 
with the basic (positively charged) residues lining the groove 
on D1. Approximately nine nucleotides are required to span 
the D1 groove; thus, a single ODN2395 molecule (22 nucle-
otides) could interact simultaneously with two GPVI dimers 
(not depicted). Accordingly, platelet binding and activation 
was detectable for PS ODN molecules of 18 or more nucleo-
tides; however, smaller PS ODN molecules did not exhibit a 
significant platelet-activating effect (not depicted). This model 
of ODN2395-induced clustering of GPVI dimers is analo-
gous to the collagen-induced mechanism of GPVI clustering 
previously proposed by Horii et al. (2006), which triggers an 
ITAM-based signaling cascade. Treatment of platelets with 
5 µM ODN2395 induced small, albeit physiologically relevant 
GPVI dimer formation, as detected by increased binding of 
an anti-GPVI dimer–specific Fab (204-FAB; Jung et al., 2012) 
by flow cytometry (Fig. 2 j) and by native gel electrophoresis 
(not depicted). It is likely that oligomeric ODN2395 can in-
teract with and cluster multiple GPVI dimers. Altogether, our 
observations indicate that the platelet receptor GPVI can bind 
PS ODNs.
GPVI is the central receptor that mediates platelet–collagen 
interaction (Nieswandt and Watson, 2003) and plays a crucial 
role in the recruitment of platelets to the injured arterial wall 
(Massberg et al., 2003). We therefore used a murine carotid 
artery ferric chloride injury model to assess potential effects of 
PS ODNs in vivo. Treatment with ODN2395 but not the 
nonmodified oligonucleotide significantly reduced occlusion 
times (Fig. 3 a). Moreover, in a laser-induced mouse mesenteric 
thrombosis model, discrete tissue injury leads to endothelial 
cell disruption and collagen exposure. This model is thereby 
considered to be associated with a prominent role for GPVI 
in thrombus formation. Significantly larger thrombi were 
quantified after ODN2395 injection as compared with PBS 
or nonmodified ODN2395 injection (Fig. 3, c and d). This 
strongly implies that ODN2395 treatment had accentuated 
the ability of platelets to form thrombi, possibly by enhanc-
ing GPVI responsiveness via clustering/dimerization. Pul-
monary embolisms ranging from small asymptomatic to large 
fatal embolisms are a potential clinical consequence of pro-
thrombotic side effects of drug therapy. Notably, pulmonary 
thrombus formation could be detected 20 min after i.v. 
injection of ODN2395 compared with PBS control or non-
modified ODN (Fig. 3 b). These mouse models confirm 
the relevance of the described platelet-activating effects of 
ODN2395 in vivo.
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Coulter, and streptavidin-PE secondary antibody from Jackson Immuno-
Research Laboratories, Inc. The single-chain antibody (scFv) SCE5 was 
generated as described previously (Schwarz et al., 2004), and binding was vi-
sualized via a Penta-His Alexa Fluor 488–conjugated antibody (QIAGEN). 
Antibodies against human CLEC-2 were generated as described previously 
(Gitz et al., 2014). Oligonucleotides ODN2395 (5-TCGTCGTTTT-
CGGCGCGCGCCG-3 with and without PS backbone), FITC-labeled 
ODN2395 (5-TCGTCGTTTTCGGCGCGCGCCG-3 with and with-
out PS backbone), scrambled ODN (5-TGCTGCTTTTGGGGGGCCC-
CCC-3, complete PS backbone), and ODN TTAGGG (TLR9 antagonist, 
5-TTTAGGGTTAGGGTTAGGGTTAGGG-3, PS backbone) were 
should be considered and appropriate hematological tests 
performed in preclinical and in particular in clinical trials. 
Our findings support the development and use of alternative 
chemical modifications to provide nuclease resistance for 
nucleotide-based therapeutics.
MATERIALS AND METHODS
Antibodies and reagents. FITC-labeled anti-GPIIb/IIIa antibody PAC-1 
and PE-labeled anti-CD62P antibody were purchased from BD, FITC- 
labeled anti-CD61 and APC-labeled anti-CD14 antibody from Beckman 
Figure 3. In vivo carotid artery injury, pulmonary 
thromboembolism, and mesenteric artery injury 
mouse models; in vitro impact of PS backbone–
modified miRNA and antisense oligonucleotide 
G3139 on platelet activation. (a) Occlusion time 
after in vivo injection of ODN2395 (0.6 mg/kg body 
weight) before carotid artery injury compared with  
PBS control (***, P < 0.001; n = 6–8) and nonmodified 
ODN2395 (0.6 mg/kg body weight; **, P < 0.01 
ODN2395 vs. ODN nonmod; n = 6). (b) Thrombus for-
mation in the lung vessels of C57BL/6 mice induced by 
ODN2395 (1 mg/kg body weight; III and IV); I, PBS 
injection; II, injection of ODN nonmod (1 mg/kg body 
weight). Images are representative for four animals/
group (control/ODN2395/ODN nonmod). (c and d) 
Thrombi size in mice injected with ODN2395 (i.v. tail 
vein injection, 1 mg/kg body weight) compared with 
PBS injection or ODN nonmod injection, respectively. 
Original pictures were taken after rhodamine staining 
(***, P < 0.001 vs. PBS and ODN nonmod; n = 4–5). 
(b and c) Bars, 100 µm. (e) PAC-1 binding after treat-
ment with miRNA (miR-322) compared with control 
untreated samples (*, P < 0.05 vs. unstim; **, P < 0.01 
vs. 1 µM miRNA; ***, P < 0.001 vs. unstim; n = 3). 
(f and g) G3139-induced platelet activation and bind-
ing in whole blood compared with non–PS-modified 
G3139 (***, P < 0.001 vs. unstim/10 µM G3139 nonmod; 
n = 6). Data are presented as means ± SEM.
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streptavidin-PE was used for samples preincubated with biotinylated ODN2395. 
After staining, blood samples were lysed with FACS lysing solution (BD), 
washed twice, and fixed with cell fix. For whole mouse blood experiments, 
blood was diluted 1:10 in PBS and stained with the appropriate antibodies, 
and platelets were gated according to size and positive staining for CD41. 
10,000 events in the platelet gate were acquired for each sample. Flow cy-
tometry of lysed blood samples was performed on a FACSCanto (BD), and 
2,500 CD14+ events were acquired for each sample to evaluate PMA for-
mation. Analysis was performed using CellQuest Pro for FACSCalibur 
measures and FACSDiva software for data acquired on FACSCanto (BD). 
Histogram overlays were generated using FlowJo 7.6.5 software.
96-well plate platelet aggregometry. PRP was obtained as described 
above, and platelet-poor plasma (PPP) was prepared by centrifugation of 
PRP (4,000 g, 5 min). After 30 min of resting at 37°C, 90 µl PRP was added 
to wells of a 96-well plate, which were prepared with different concentra-
tions of agonists. The plate was then immediately placed in a 96-well plate 
reader, and absorbance was determined at 595 nm every 30 s for 60 min be-
tween vigorous shaking at 37°C. As reference for maximal and minimal ag-
gregation, PPP and PRP were used, respectively.
Microfluidics assay. Discrete ligand patches were immobilized in micro-
fluidic devices by infusing the ligand solution (100 µg/ml collagen type III 
and 100 µg/ml fibrinogen) through separate microfluidic “coating” chan-
nels. The ligands were allowed to adsorb to the glass surface for 2 h at RT, 
and unspecific binding sites were blocked by perfusion of 1% BSA. After 
removal of the coating channels, a second set of microfluidic channels was 
placed perpendicular to the direction of the first channel. Perfusion of prein-
cubated whole blood samples results in thrombus formation selectively at 
the discrete coating strips. Vehicle, 5 µM ODN2395, and 5 µM ODN2395 
nonmod preincubated samples were perfused for 5 min at a shear rate of 
400/s, and formed thrombi were fixed with 1% formaldehyde solution. 
Flow experiments were performed using an IX81 Olympus microscope, and 
platelet adhesion was visualized in real time.
Differential interference contrast (DIC) microscopy of adhering 
platelets. Glass coverslips were coated with 30 µg/ml fibrinogen at 4°C 
overnight. After washing with PBS, coverslips were blocked with 1% BSA. 
After adding 5 µM ODN2395 or ODN2395 nonmod, washed platelets were 
instantly added to the coverslips and incubated for the indicated time points 
at 37°C. Samples were then washed twice with PBS and fixed with cell fix 
for 15 min. Finally, DIC (100×) was performed on an Olympus BX61 mi-
croscope using an F-View II digital camera.
Intracellular ROS production in platelets. Agonist-induced intracellu-
lar ROS production in platelets was quantified by flow cytometry using 
2,7-dichlorodihydrofluorescein diacetate (H2DCF-DA) as described previ-
ously (Arthur et al., 2012). Dye-loaded platelets were mixed with agonists 
for up to 20 min and then diluted 10-fold. The stimulation index represents 
the ratio of mean percentage of events within the gate region (M1) of the 
resting versus the agonist-treated sample.
Modeling of potential ODN2395 interactions with GPVI. Poisson-
Boltzmann electrostatics were calculated for the extracellular GPVI CBD 
dimer (PDB ID: 2GI7; Horii et al., 2006) using the APBS Tools 2.1 plugin 
for PyMOL v1.6.0.0 (http://www.pymol.org). CRP (PDB ID: 1CAG) was 
manually docked into the collagen-binding site on D1 of a GPVI monomer 
using the collagen-binding residues identified from site-directed mutagenesis 
experiments (Horii et al., 2006) as a guide. The rigid body docking was per-
formed manually within SYBYL-X 2.1 (Certara, L.P.). The phosphodiester 
version of ODN2395 (ODN2395 nonmod) was constructed within SYBYL-
X 2.1 in a random, linear-like conformation. To obtain the PS-modified ver-
sion of ODN2395, one of the nonbridging oxygen atoms in each of the 22 
nucleotides was replaced with a sulfur atom, and the bond length was adjusted 
to 1.9 Å; the oxygen replacement was performed in a random manner to obtain 
purchased from InvivoGen, biotin-labeled ODNs and G3139 (5-TCTCC-
CAGCGTGCGCCAT-3, PS backbone) from GeneWorks, and miRNA 
targeting nucleotides (miR-322, 5-GGUUUUGUACUUAACGACGAC-3, 
PS backbone) from Exiqon. Unless stated otherwise, all other chemicals 
were obtained from Sigma-Aldrich.
Blood collection from healthy human subjects. Healthy blood donors 
provided informed consent in accordance with the Declaration of Helsinki. 
All subjects were free of platelet-affecting drugs for at least 14 d. Blood sam-
pling procedures were approved by the Ethics Committee of the Alfred 
Hospital, Melbourne, Australia.
Preparation of PRP and washed platelets. Blood was collected by veni-
puncture with a 21-gauge butterfly needle from healthy volunteers into citrate 
anticoagulant (Monovette; Sarstedt). PRP was isolated by centrifugation at 
180 g for 10 min. Washed platelets were prepared from PRP by two additional 
washing/centrifugation steps (500 g, 10 min) in the presence of ACD (acid 
citrate dextrose) buffer, 0.05 µM PGE1, and 0.01 U/ml apyrase. The final 
platelet pellet was resuspended in Tyrode’s buffer (137 mmol/liter NaCl, 
2.68 mmol/liter KCl, 11 mmol/liter NaHCO3, 10 mM Hepes, 0.42 mM 
NaH2PO4, and 5 mM d-Glucose, pH 7.4) in the same volume as initial PRP 
and substituted with 1 mM MgCl2 and 2 mM CaCl2 (final concentration).
Pull-down with ODN-coated streptavidin beads. Washed platelets 
were lysed in lysis buffer (150 mM NaCl, 1% Triton X-100, and 50 mM 
Tris, pH 8.8) and precleared by incubation with streptavidin beads for 10 min 
at room temperature (RT); beads coated with either ODN2395-Biotin 
or ODN nonmod–Biotin (5 µM final concentration) were mixed with 
cleared platelet lysates for 30 min at RT with rocking. Beads were then pel-
leted and washed three times with PBS; bead-associated proteins were eluted 
into 5× Laemmli sample buffer and heated for 5 min at 96°C, then separated 
by 12% SDS-PAGE and electrotransferred to a polyvinylidene difluoride 
(PVDF) membrane, and stained with 1 µg/ml anti-GPVI antibody (1G5; 
Al-Tamimi et al., 2009).
Assessment of ODN2395-mediated tyrosine phosphorylation. Washed 
platelets were treated with 5 µg/ml CRP-XL, 5 µM ODN2395, or 5 µM 
nonmodified ODN2395 for 20 min before addition of ice-cold lysis buffer 
containing 5 mM EGTA, 1% (vol/vol) Triton X-100, 20 mM Tris-HCl, 
pH 7.4, and complete protease and phosphatase inhibitor cocktail (Roche). 
Lysates were centrifuged at 1,000 g for 5 min, and supernatants were incu-
bated overnight with either 5 µg/ml mouse anti-Src antibody or mouse 
anti-Syk antibody (GD11 or 4D10.1; EMD Millipore). Src or Syk was then 
pulled down from the lysates using Protein A–coated beads (GE Healthcare). 
After washing these beads twice with 0.1% (vol/vol) Tween-20 in PBS, 
proteins were then eluted by boiling for 10 min in 2× reducing SDS sample 
loading buffer, and proteins in the eluted fraction were separated by SDS-
PAGE followed by electrotransfer to nitrocellulose. Filters were blocked 
with 20 mM Tris-HCl, pH 7.4, containing 5% (wt/vol) skim milk and then 
probed with 0.5 µg/ml 4G10 anti-phosphotyrosine antibody (EMD Millipore), 
1 µg/ml anti-Src antibody, or 0.5 µg/ml anti-Syk antibody in 20 mM Tris-
HCl, pH 7.4, containing 3% (wt/vol) BSA and 0.1% (vol/vol) Tween-20 
and visualized using HRP-conjugated anti–mouse IgG antibody and enhanced 
chemiluminescence (GE Healthcare).
Flow cytometry. To investigate platelet activation, PRP or washed plate-
lets, respectively, were stimulated with oligonucleotides at different concen-
trations or 20 µM ADP as positive control for 10 min. Thereafter, samples 
were stained with the appropriate antibodies (PAC-1–FITC and CD62-PE) 
for 20 min and finally fixed with cell fix (BD). To evaluate platelet-leukocyte 
aggregates and binding of biotinylated ODNs in whole blood, citrated whole 
blood was incubated with ODNs (1 µM/5 µM) or ADP (20 µM) for 10 min 
and stained with the appropriate antibodies. Anti–CD61-FITC was used to 
define the platelet population, anti–CD14-APC as a monocyte marker, 
and anti–CD3-PE as a lymphocyte marker. To analyze ODN binding, 
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an oligonucleotide of mixed stereochemistry (i.e., not all Rp or Sp chirality). 
The PS-ODN2395 was manually docked into the GPVI D1 groove.
Ex vivo and in vivo tests of ODNs in mice. All experiments involving 
animals were approved by the AMREP animal ethics committee. C57BL/6 
mice or TLR9/ on C57BL/6 background were anaesthetized with 50 mg/kg 
ketamine and 10 mg/kg xylazine. For ex vivo experiments, the abdominal 
cavity was opened under deep anesthesia and blood was taken by direct punc-
ture of the inferior caval vein into a tube containing 3.8% sodium citrate.
Carotid artery occlusion time model. The left jugular vein was revealed in 
male C57BL/6 mice (20–25 g) by an incision to inject reagents. A further inci-
sion was made on the right neck to allow careful dissection of the common 
right carotid artery from its connective tissue. 5 min after the injection of the 
experimental reagents, a 1 × 5–mm strip of filter paper soaked in 10% ferric-
chloride solution was inserted under the vessel for 3 min to cause an injury, 
which when left untreated will consistently occlude. After 3-min injury, the 
filter paper was removed, the area was flushed with saline, and a Doppler flow 
probe (Transonic 0.5 mm) was fitted around the site of injury. Flow speed and 
time of occlusion were reported.
Laser-induced vessel wall injury in mesenteric arteries. Young male 
C57BL/6 mice (15–18 g) were chosen to minimize fat surrounding of the ves-
sels. After inferior caval vein injection of 70 µl of 0.05% rhodamine solution 
and subsequent injection of ODN2395 or ODN2395 nonmod (1 mg/kg 
body weight) or PBS, the mesentery was exposed. A localized laser injury 
(440-nm pulsed nitrogen dye laser) was induced to arteries of 70–100 µm 
in diameter through the objective (20×) of an inverted IX81 microscope 
(Olympus) with a Micropoint laser system (Photonics Instruments).
Murine pulmonary thromboembolism. Anesthetized male C57BL/6 
mice (20–25 g) received i.v. ODN2395 or ODN2395 nonmod (1 mg/kg body 
weight) or PBS. After 20 min, mice were euthanized and perfusion was per-
formed with 6 ml saline, followed by 6 ml of 10% formalin. Lungs were sub-
sequently removed and fixed for 2 d with 10% neutral-buffered formalin. 
These organs were then embedded in Tissue-Tek OCT compound (Sakura) 
and stored at 80°C until use.
Lung cryosections of 8 µm were prepared. After antigen retrieval with 
20 µg/ml Proteinase K buffer, thrombi were detected by incubating tissue sec-
tions with rat anti–mouse CD41 IgG overnight (clone: MWReg30; AbD Sero-
tec) at 5 µg/ml or saline. Subsequent steps were performed using the Rat IgG 
VECTASTAIN ABC kit (Vector Laboratories) in which stain was developed 
using 3,3-Diaminobenzidine (DAB)–peroxidase substrate. The sections were 
counterstained with Mayer’s hematoxylin and examined using an Olympus BX50 
microscope and image captured with MicroPublisher 3.3 RTV digital camera 
(QIMAGING). For quantification, thrombi of 10 transverse cryosections (200 µm 
apart) of each lobe (left and right superior and right middle) were counted.
Statistics. Data are presented as means ± SEM and were analyzed using 
two-tailed Student’s t test or one-way ANOVA with a Tukey post-hoc test. 
P < 0.05 was considered statistically significant.
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